market as the leader, integrating scientific research, clinic, production and marketing, and applying modern high-tech research on traditional Chinese medicine and biological medicine for the treatment of difficult diseases. In the course of the development of the group of companies, the accumulation of a profound corporate culture, cohesion of a large number of innovative, willing to dedication to the pharmaceutical doctorate, masters and other high-tech personnel. The company is a post-doctoral research station of the Ministry of Personnel of the State. The high-quality talent team and the platform of high technology and equipments have made the research and development and production of modern Chinese medicine and biopharmaceuticals make world-renowned achievements, and relying on its own institutional advantages, it has realized industrialization and internationalization, and it has developed into a modern pharmaceutical group with greater influence in China, and with five major branches. Entering the new century, Ealing people will continue to carry forward the enterprise spirit of "unity, progress, integrity and dedication", take the revitalization of the national medicine as the responsibility, strive to build the brand of national medicine, follow the frontiers of pharmaceutical science and technology, build the international leading products, build up the platform of science and technology and the market, and sincerely cooperate with friends from all walks of life to realize the grand goal of the enterprise. Strive for the realization of the enterprise's ambitious goal of "Committed to Science and Technology, Healthy Tomorrow". Ealing Pharmaceuticals, located in the high-tech development zone of Shijiazhuang City, Hebei Province, was founded in 1992 by Prof. Wu Yiling, an academician of the Chinese Academy of Engineering, the chief scientist of the National 973 Project and a doctoral supervisor. After more than ten years of development, it has become a modern pharmaceutical high-tech industrial group integrating scientific research, teaching, clinic, production and marketing with six branches, including Ealing Pharmaceutical Research Institute, Shijiazhuang Ealing Pharmaceutical Company Limited, Hebei Ealing Hospital, Anguo Ealing Traditional Chinese Medicine Drinking Tablets Company Limited, Beijing Ealing Pharmaceutical Company, and Beijing Ealing Biological Company Limited. It is one of the top 100 pharmaceutical companies in China and one of the top 10 companies in China in terms of independent innovation ability in the proprietary Chinese medicine manufacturing industry, and has been awarded hundreds of honorary titles, such as National Key High-tech Enterprise, Leading Enterprise of Pharmaceutical Manufacturing Industry, Pharmaceutical Enterprise Contribution to Social Responsibility Award, Honest Enterprise of Hebei Province, and the Most Socially Responsible Enterprise of Hebei Province. Ealing Pharmaceuticals insists on taking science and technology as the forerunner, taking the market as the leader, driving the industrialization of traditional Chinese medicine with the academic innovation of traditional Chinese medicine, and applying modern high-tech to research and develop traditional Chinese medicine, western medicine and biological medicine. Based on Ealing Pharmaceutical Research Institute, it is recognized as National Enterprise Technology Center, Postdoctoral Research Station, National 863 Achievement Transformation Base, the first international scientific and technological cooperation bases, Hebei Traditional Chinese Medicine R & D and Achievement Industrialization Center, and Shijiazhuang Compound Traditional Chinese Medicine Engineering R & D Center. Has undertaken the National 973, National 863, the National Tenth Five-Year Plan, the National Natural Science Foundation of China and other national, provincial and ministerial-level projects more than 30, more than 100 domestic and foreign invention patents, won the second prize of the National Science and Technology Progress Award, the second prize of the National Technological Invention Award, and other national, provincial and ministerial-level scientific and technological awards more than 20. It has developed a series of national new drugs with independent intellectual property rights and rapidly industrialized them, taking a new way to accelerate the development of Chinese medicine through academic innovation. Ealing Pharmaceuticals has formed a product group led by Tongxinluo Capsule, Ginseng Pine Nourishing Heart Capsule, Lianhua Qingdian Capsule, and has listed 9 patented new drugs and more than a hundred of generic and imitation drugs, and the subsequent research and development will make the product series more complete. Tongxinluo Capsule is the only Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases that has won three national awards, and it has become the leading brand of Chinese patent medicines for the treatment of cardiovascular and cerebrovascular diseases, and it is ranked the top three among the similar varieties in the domestic market. Lianhua Qingdian Capsule is a high-tech demonstration project of the National Development and Reform Commission and a national OTC category A variety, which has played an important role in the fight against SARS, avian influenza and the current global outbreak of influenza A. The capsule has been widely used in the treatment of cardiovascular and cerebrovascular diseases. A number of domestic authoritative scientific research machine a large number of scientific research confirms that it can be broad-spectrum antiviral, effective antibacterial, antipyretic and anti-inflammatory, effectively improve the fever, sore throat, cough and other symptoms, enhance immunity, improve the body's ability to fight and recover from diseases, anti-H1N1 influenza A virus is better than Tamiflu. Ginseng Song Nourishing Heart Capsules is the only proprietary Chinese medicine in China that carries out evidence-based clinical research on anti-arrhythmia, and its clinical efficacy and safety have been unanimously recognized by medical experts and consumers, which plays a positive role in the modernization and internationalization of China's clinical research on traditional Chinese medicine. Ealing Pharmaceutical Research Institute is the leader of the Group's development, and has built a modern high-tech R&D platform in line with the GLP standard, with more than 100 scientific researchers, 18 returnees with PhDs and post-doctoral degrees, 27 master's degrees, and 35 people with titles of associate high school or above, and cooperates with academicians and experts from renowned colleges and scientific research institutes at home and abroad to carry out research and development projects, and this powerful team of talents provides a strong technical support for the research and development of new drugs. The strong talent team provides strong technical support for the research and development of new drugs, and over the past ten years, it has researched and developed 8 national new drugs with independent intellectual property rights. Ealing Institute of Pharmaceutical Sciences has set up Pharmacy Department, Pharmacology Department, Clinical Department and Registration and Patent Department, equipped with analytical instruments with world advanced level such as high performance liquid chromatography, gas chromatography, thin layer scanning, atomic absorption, nuclear magnetic *** vibration, infrared spectroscopy, gas chromatography, etc., and advanced technological research equipments such as supercritical extraction, adsorption and separation, membrane separation, nano-preparation, etc. as well as complete pilot plant, and has established the extraction, separation, purification, and purification of the active ingredients or active parts of the modern Chinese traditional medicine. The research system of extraction, separation and purification of active ingredients or effective parts of traditional Chinese medicine and the quality control system of fingerprinting of traditional Chinese medicine have been established. Ealing Pharmaceutical Research Institute is capable of researching and developing traditional Chinese medicine compound, traditional Chinese medicine monomers, traditional Chinese medicine components, various types of new medicines, and generic drugs of western medicines, and it has become a drug research and development organization with certain influence in China. Shijiazhuang Ealing Pharmaceutical owns production lines of capsules, soft capsules, tablets, granules, injections and drop pills certified by GMP and ISO9001 quality system, and production workshops for chemical medicines in line with EU certification standards and under the guidance of foreign expert groups, with an annual output value of up to 5 billion RMB. Ealing Pharmaceuticals has introduced advanced equipments and technologies in all aspects of large-scale production of traditional Chinese medicines, and has enhanced the quality of modern traditional Chinese medicines by adopting advanced technologies such as dynamic extraction, external circulation concentration, CO2 supercritical extraction, high-speed centrifugal spray drying, and one-step granulation. With Tsinghua University***, we undertook the National High-Tech Development Program Project - Tongxinluo Capsule Ultra-micro-powder Process Enhancement Project, which was the first time that the ultra-micro-powder technology was successfully applied to the production of pCms, and became a national standard and won the national award. Modernized production lines, reliable product quality and strong production capacity ensure that the scientific research results are quickly transformed into high-quality new products for the market. Ltd. is the raw material base of Ealing Pharmaceutical Group. Located in Anguo, the capital of medicine, the company covers an area of 20,000m2 and a building area of 10,000m2, and is a modernized enterprise integrating standardized cultivation (farming) of centralized medicinal herbs, traditional Chinese medicine tablets, and the processing and trade of refined tablets, and it took the lead in passing the GMP certification of Chinese medicine tablets by the State Food and Drug Administration in 2004. In 2004, the company took the lead in passing the GMP certification of Chinese medicine tablets by the State Food and Drug Administration. In order to ensure the quality of raw materials, the company has established planting and breeding bases in accordance with GAP requirements in Anguo, Jilin, Gucheng, etc., and established QA, QC quality assurance system. The company also carries out processing and sales of traditional Chinese medicinal tablets, and has established good business relationships with thousands of hospitals and pharmaceutical companies.